Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 27;9(2):20552173231169463. doi: 10.1177/20552173231169463

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Unadjusted sNfL levels for individual patients at baseline and month 36 in the (a) IM IFN beta-1a, (b) GA, and (c) IM IFN beta-1a + GA, and (c) IM IFN beta-1a +GA treatment groups. The p-value indicates the significance of the change in the proportion of patients with sNfL ≥16 pg/mL from baseline to month 36. Comparisons were adjusted for age, sex, the presence of gadolinium-enhancing lesions, Expanded Disability Status Scale score, baseline sNfL level, and actual body mass index. GA: glatiramer acetate; IFN: interferon; IM: intramuscular; sNfL: serum neurofilament light-chain.